WADA’s 2027 Banned List Clarifies Rules for Experimental Peptides

Why the wording matters

WADA’s 2027 Prohibited List sharpens the message for athletes considering experimental performance drugs: a substance doesn’t need to be named individually to fall under anti-doping rules. The list takes effect Jan. 1 and explicitly includes peptides in its category for non-approved substances. The U.S. Anti-Doping Agency has advised athletes not to treat an unfamiliar compound’s absence from the list as permission to use it. That warning addresses a practical gap between how athletes often search for information and how the rules work: a name-by-name lookup can’t establish that an unlisted substance is allowed.

That clarification matters in a market where legitimate medicines sit alongside early-stage research compounds and products making claims that outpace the evidence. A product’s marketing language can make a compound sound established even when its status and effects remain uncertain. For athletes, the label “research use only” offers no assurance about safety, quality or anti-doping status. It describes how a product is presented, not whether it’s suitable for human use or permitted in sport.

Peptides aren’t all treated the same

WADA hasn’t banned every peptide. Peptides are chains of amino acids, and some are approved medicines; insulin is one example. The S0 category applies to pharmacological substances that have no approval for human therapeutic use from any government health authority, unless another prohibited category already covers them. Adding “peptides” to S0 clarifies how that category applies. It doesn’t make every peptide medication prohibited, and it doesn’t erase the distinction between an approved medicine and an experimental compound.

That distinction can be easy to lose in online discussions, where “peptide” is sometimes treated as if it describes one uniform class of drug. It doesn’t. The category covers substances with different purposes and levels of medical recognition, so athletes can’t safely infer a substance’s status from its broad label alone. They need to consider whether it has approval for human therapeutic use and whether another part of the list applies.

Nor does the wording mean experimental peptides were permitted before. BPC-157 was already prohibited under the rules for non-approved substances, while some growth-hormone-related compounds fall under other categories. The updated language makes it harder to argue that an unlisted research compound escapes the rules simply because its name doesn’t appear in the document. That’s a clarification of how the existing framework applies, rather than evidence that every peptide has acquired the same status.

WADA also added examples elsewhere in the list. SLU-PP-332 and SLU-PP-915, both experimental metabolic modulators, are named in the hormone and metabolic modulators category. Eplerenone and finerenone appear as examples of diuretics and masking agents, despite having legitimate medical uses. These examples help show that the list can identify substances by category and include named illustrations. A drug’s medical purpose doesn’t by itself determine whether it’s allowed in sport; athletes still have to establish its status under the applicable rules.

Monitoring isn’t a ban

Semaglutide and tirzepatide, used in weight-loss and diabetes treatments, remain on WADA’s 2027 monitoring program. That means WADA is tracking their use in sport; it hasn’t placed them on the prohibited list. Caffeine is also monitored in competition without being prohibited. Athletes need to distinguish surveillance from a ban when checking a substance’s status, because the presence of a compound on a monitoring program doesn’t answer the same question as its inclusion on the prohibited list.

Monitoring can indicate that WADA is paying attention to a substance’s use, but it shouldn’t be read as an advance verdict about what the organization will do later. The facts here establish only the current distinction: the named medicines are monitored, not prohibited under the 2027 list. If you’re working in this space, that difference matters when explaining the rules to athletes who may interpret any mention by WADA as a ban. Here’s the thing: category and status are more useful than a quick scan for a familiar drug name.

The list also clarifies its treatment of cannabis. Psychoactive THC-related cannabinoids, including some synthetic and semi-synthetic versions, are prohibited in competition. CBD itself isn’t prohibited, but a CBD product with undeclared THC can still lead to a failed drug test. That creates a product-level problem: an athlete may choose CBD while a product’s actual contents include a prohibited substance that isn’t disclosed on its label.

Check before taking a substance

Anti-doping rules make athletes responsible for what enters their bodies. Missing ingredients on a product label, or assurances from a coach or doctor, may not protect a competitor if a test detects a prohibited substance. That makes independent checks especially important when a product’s contents or status are unclear. The responsibility doesn’t become simpler just because a substance is sold openly or described as a supplement.

For athletes, the practical challenge is that a product name, a research label and a claim about performance each answer different questions. None establishes whether the ingredients are accurately disclosed, whether the compound has approval for human therapeutic use, or whether the rules prohibit it. Those checks can require looking beyond the package and confirming the substance’s status through anti-doping resources. And this is the part most people overlook: a label can tell you how a seller wants the product understood, while the anti-doping rules classify the substance itself.

Research into performance drugs can produce useful discoveries, but an early study or anecdotal report doesn’t establish that a compound is safe or effective in humans. Athletes may still be tempted by claims of improved recovery or performance, especially when a substance seems difficult to detect. Yet the presence or absence of a test doesn’t determine whether a substance is permitted. Detection and permission are separate questions, and claims about one don’t settle the other.

What the update signals for athletes

WADA’s updated wording puts the focus on the substance’s approval and category, not just whether its name appears on the list. This is more significant than it looks: it pushes athletes and the people advising them to interpret the rules by their underlying criteria, rather than treating the list as a complete catalog of every possible compound. That approach is especially relevant as research products circulate under unfamiliar names and claims that may change faster than public understanding of their risks.

The limits of the message matter, too. The update doesn’t make every peptide prohibited, and monitoring doesn’t equal a ban. But an absent name isn’t a reliable green light when the list’s categories can cover substances that aren’t individually identified. Athletes weighing an experimental peptide should confirm its status before using it, with Jan. 1 marking the start of the revised rules. The simplest takeaway is also the least convenient: check the category and approval status, not just the product name. A name missing from the page. That alone settles nothing.